findmyKOL
Clinical trialNCT06143553RecruitingPhase 3Interventional

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

SponsorShanghai Yizhong Pharmaceutical Co., Ltd.Enrollment168Metastatic Breast Cancer (MBC)
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

    Recruiting
  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

    Recruiting
  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
25 Sept 2023
Primary completion
31 Dec 2025
Completion
31 Dec 2025
Last update posted
29 Nov 2024
Registered enrollment
168
Registry id
NCT06143553

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.